Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7070 in Patients With Gastric Cancer
NCT00165594Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2005
- Primary completion
- Jul 2006
- Modality
- RNA-Targeting Small Molecules, Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indisulam in gastric cancer (GC), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting toxicity and Response Rate. Started Feb 2005; status: terminated.
02
Drugs
indisulam
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00165594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165594.